Year: 2015
Type: article
Abstract: “High risk” groups for exacerbations of chronic obstructive pulmonary disease (COPD) in the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) proposal ( i.e. groups C and D) [1] include: patients with a forced expiratory volume in 1 s FEV1 <50% reference and <2 exacerbations year-1 (subgroups C1 and D1); patients with ≥2 exacerbations·year-1 and an FEV1 ≥50% reference (subgroups C2 and D2); and patients with both FEV1 <50% ref. and ≥2 exacerbations·year-1 (subgroups C3 and D3) [2–5]. We hypothesised that these high-risk subgroups will differ in other clinical, functional and biological characteristics and will be associated with different long-term outcomes. We explored this hypothesis in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) cohort [6, 7]. The results of this study show that “high-risk” COPD patients (GOLD groups C and D) are highly heterogeneous <http://ow.ly/LTMOv> Authors thank all participants for their willingness to contribute to advance medical science in the field of COPD.
Source: European Respiratory Journal
Institutions: Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, University of Nebraska Medical Center, GlaxoSmithKline (United States), University of Edinburgh, Maastricht University Medical Centre, GlaxoSmithKline (United Kingdom), Brigham and Women's Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: GlaxoSmithKline
OpenAlex ID: W2150074163